Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RYZ811 and RYZ801 in GPC3+ Unresectable Hepatocellular Carcinoma
NCT06726161Phase 2Recruiting
- Sponsor
- RayzeBio
- Start
- Sep 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of RYZ801 in hepatocellular carcinoma (HCC), sponsored by RayzeBio. Started Sep 2025; status: recruiting.
02
Drugs
RYZ801
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06726161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726161.